Search results
Alison Lawton (born May 29, 1970) is a Canadian social venture philanthropist, social advocate, and business investor.
Alison Lawton is the founder and president of Mindset Venture Group, a company that invests in early-stage businesses and social ventures. She has a diverse portfolio of investments in technology, consumer, and real estate sectors, and is also involved in global health and social impact initiatives.
Alison Lawton most recently served as Kaleido’s Chief Executive Officer, President and as a member of the Board of Directors since August 2018, after initially joining the company as President and Chief Operating Officer in December 2017. Ms.
Alison Lawton is a social venture philanthropist and the founder of Mindset Social Innovation Foundation, a non-profit that supports global health and social enterprises. She has worked with various organizations, including Virgin Unite, The Clinton Foundation, and UNICEF Canada, and is also involved in impact investing and LGBTQ+ issues.
Alison Lawton is an experienced biopharma executive and a board member of Dianthus Therapeutics, a company developing gene therapy for rare diseases. She has served as CEO of Kaleido Biosciences and COO of Aura Biosciences, among other roles.
BlueRock is a biotechnology company that develops cell therapies for various diseases. Alison Lawton is not mentioned on the web page, which introduces the executive team, board of directors, scientific advisors, and collaborators of BlueRock.
Alison Lawton is a seasoned biotech executive with experience as CEO, Chair and independent director of several companies. She is currently working at Dianthus Therapeutics, Inc. and has a degree from King's College London.
